Article

Deal is off: LaserSight, third party terminate AstraMax sale

Winter Park, FL-LaserSight Inc. and a third-party buyer have ended an agreement to buy LaserSight's AstraMax technology over an exclusivity dispute.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
Related Content
Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye
August 5th 2025

Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye

3 Things You Should Know About the GA Pipeline
August 5th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Alcon announces US launch of Tryptyr (acoltremon ophthalmic solution) 0.003% for dry eye disease
August 5th 2025

Alcon announces US launch of Tryptyr (acoltremon ophthalmic solution) 0.003% for dry eye disease

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 5th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: The potential impact of vitamin D on retinal surgery
August 5th 2025

Q&A: The potential impact of vitamin D on retinal surgery

Handheld fundus camera from Optomed USA launched for use in any care setting
August 5th 2025

Handheld fundus camera from Optomed USA launched for use in any care setting

© 2025 MJH Life Sciences

All rights reserved.